$20.295
-0.705[-3.36%]
Last update: 2:10PM Get Real Time Here
Akero Therapeutics
(NASDAQ:AKRO)Akero Therapeutics Stock (NASDAQ:AKRO), Analyst Ratings, Price Targets, Predictions
Akero Therapeutics Inc has a consensus price target of $42.09, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, UBS, and HC Wainwright & Co. on April 22, 2024, March 5, 2024, and March 5, 2024. With an average price target of $40.67 between B of A Securities, UBS, and HC Wainwright & Co., there's an implied 100.38% upside for Akero Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
UBS
HC Wainwright & Co.
JP Morgan
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Akero Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 47.82% | B of A Securities | Alexandria Hammond | → $30 | Reinstates | → Neutral | Get Alert |
| 03/05/2024 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 106.95% | UBS | Eliana Merle | $39 → $42 | Maintains | Buy | Get Alert |
| 03/05/2024 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 146.37% | HC Wainwright & Co. | Ed Arce | $43 → $50 | Maintains | Buy | Get Alert |
| 03/01/2024 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 111.87% | HC Wainwright & Co. | Ed Arce | $40 → $43 | Maintains | Buy | Get Alert |
| 11/14/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 97.09% | HC Wainwright & Co. | Ed Arce | → $40 | Reiterates | Buy → Buy | Get Alert |
| 10/12/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 92.17% | UBS | Eliana Merle | $83 → $39 | Maintains | Buy | Get Alert |
| 10/11/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 102.02% | JP Morgan | Eric Joseph | $62 → $41 | Maintains | Overweight | Get Alert |
| 10/11/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 97.09% | HC Wainwright & Co. | Ed Arce | $64 → $40 | Maintains | Buy | Get Alert |
| 10/11/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 92.17% | Cantor Fitzgerald | Prakhar Agrawal | $69 → $39 | Maintains | Overweight | Get Alert |
| 10/11/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 62.6% | Morgan Stanley | Michael Ulz | $70 → $33 | Maintains | Overweight | Get Alert |
| 10/04/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 239.99% | Cantor Fitzgerald | Prakhar Agrawal | → $69 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 239.99% | Cantor Fitzgerald | Prakhar Agrawal | → $69 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 195.64% | Evercore ISI Group | Liisa Bayko | $50 → $60 | Maintains | Outperform | Get Alert |
| 09/05/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 205.49% | JP Morgan | Eric Joseph | $49 → $62 | Maintains | Overweight | Get Alert |
| 08/28/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 308.97% | UBS | Eliana Merle | → $83 | Initiates | → Buy | Get Alert |
| 06/12/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 244.91% | Morgan Stanley | Michael Ulz | $65 → $70 | Maintains | Overweight | Get Alert |
| 06/07/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 215.35% | HC Wainwright & Co. | Ed Arce | $62 → $64 | Maintains | Buy | Get Alert |
| 05/17/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 190.71% | Canaccord Genuity | Edward Nash | $58 → $59 | Maintains | Buy | Get Alert |
| 05/16/2023 | AKRO | Buy Now | Akero Therapeutics | $20.30 | 205.49% | HC Wainwright & Co. | Ed Arce | $64 → $62 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Akero Therapeutics (AKRO)?
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by B of A Securities on April 22, 2024. The analyst firm set a price target for $30.00 expecting AKRO to rise to within 12 months (a possible 47.82% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
The latest analyst rating for Akero Therapeutics (NASDAQ: AKRO) was provided by B of A Securities, and Akero Therapeutics their neutral rating.
When was the last upgrade for Akero Therapeutics (AKRO)?
The last upgrade for Akero Therapeutics Inc happened on January 27, 2023 when Morgan Stanley raised their price target to $65. Morgan Stanley previously had an equal-weight for Akero Therapeutics Inc.
When was the last downgrade for Akero Therapeutics (AKRO)?
The last downgrade for Akero Therapeutics Inc happened on October 19, 2021 when Morgan Stanley changed their price target from N/A to $27 for Akero Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a with a price target of $0.00 to $30.00. The current price Akero Therapeutics (AKRO) is trading at is $20.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.